May 12, 2026 07:00AM
Mar 26, 2026 07:00AM
Mar 17, 2026 08:00AM
Mar 17, 2026 08:00AM
Mar 3, 2026 08:00AM
Mar 3, 2026 08:00AM
Jan 27, 2026 05:59AM Acumen Pharmaceuticals, Inc. (ABOS) PT Raised to $7 at BTIG
Dec 2, 2025 08:00AM
Dec 2, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 17, 2025 08:00AM
Nov 17, 2025 08:00AM
Nov 12, 2025 07:00AM Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
Aug 12, 2025 07:00AM
Jul 28, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 15, 2025 07:01AM
Jul 15, 2025 07:00AM
Jul 10, 2025 08:00AM
May 13, 2025 07:00AM Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
Apr 2, 2025 07:00AM
Apr 2, 2025 07:00AM
Apr 1, 2025 07:00AM
Mar 27, 2025 07:00AM
Mar 26, 2025 08:05AM
Mar 26, 2025 08:00AM
Mar 19, 2025 08:00AM Acumen Pharmaceuticals (ABOS) Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
Mar 19, 2025 08:00AM
Mar 12, 2025 08:00AM
Jan 9, 2025 08:00AM
Nov 12, 2024 07:00AM
Nov 6, 2024 08:01AM
Nov 6, 2024 08:00AM
Nov 6, 2024 08:00AM Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
Oct 31, 2024 08:05AM
Oct 23, 2024 08:02AM
Oct 23, 2024 08:00AM
Sep 26, 2024 08:02AM
Sep 26, 2024 08:00AM
Aug 13, 2024 07:00AM
Jul 29, 2024 07:00AM Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
Jul 28, 2024 07:30AM
Jul 11, 2024 08:00AM
May 14, 2024 07:00AM
May 8, 2024 08:00AM
Apr 16, 2024 08:00AM
Mar 26, 2024 07:00AM
Mar 21, 2024 08:00AM Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
Mar 8, 2024 08:50AM

322,899 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All